← Return to Boehringer Ingelheim AIRTIVITY clinical trial
DiscussionBoehringer Ingelheim AIRTIVITY clinical trial
MAC & Bronchiectasis | Last Active: Jul 6 7:30am | Replies (48)Comment receiving replies
Replies to "Yes, that's great to have the option of starting the real drug after the trial. Good..."
She frequently felt unwell and experienced multiple exacerbations each year. These recurring illnesses disrupted her ability to maintain full-time work, leading to significant anxiety.
Living alone, she often felt vulnerable and uncertain about her future. The demands of daily airway clearance and exercise routines consumed much of her limited free time.
Brensocatib changed everything. She now feels clearer, both physically and mentally, and has reclaimed valuable time in her day. Although she was eligible to retire last year, she felt well enough to continue working a bit longer—giving her the opportunity to boost her retirement savings so in addition to buying a small home she might also travel.